LOGIN  |  REGISTER
C4 Therapeutics
Cue Biopharma

UnitedHealth Provides Updates on Annual Shareholder Meeting, Board Actions

June 05, 2024 | Last Trade: US$307.70 3.99 1.31

- / Jun 05, 2024 / Business Wire / UnitedHealth Group (NYSE: UNH) provided updates on its 2024 annual shareholder meeting and actions by its Board of Directors.

Shareholders elected all those nominated to the Board: Charles Baker, Timothy Flynn, Paul Garcia, Kristen Gil, Stephen Hemsley, Michele Hooper, F. William McNabb III, Valerie Montgomery Rice, M.D., John Noseworthy, M.D., and Andrew Witty.

UnitedHealth Group directors stand for election annually.

Shareholders also:

  • Approved the advisory resolution on the Company’s executive compensation.
  • Ratified Deloitte & Touche LLP as the Company’s independent registered public accounting firm.
  • Voted against the shareholder proposal seeking a political contributions congruency report.

At its regular quarterly meeting, the Board authorized payment of a cash dividend of $2.10 per share, to be paid June 25, 2024, to common stock shareholders of record as of the close of business June 17, 2024.

About UnitedHealth Group

UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow UnitedHealth Group on LinkedIn.

Astria Therapeutics

Stock Quote

Last Trade: US$307.70
Daily Change: 3.99 1.31
Daily Volume: 7,594,987
Market Cap: US$279.130B

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page